|
Tuesday
|
Wednesday
|
Thursday
|
Friday
|
Saturday
|
|
THURSDAY, DECEMBER 12, 2019 |
|
|
|
|
| 6:45 am - 5:15 pm
|
Registration - Main Lobby |
|
| |
|
|
| 7:00 am - 9:00 am |
SPOTLIGHT SESSION 4: Targeting HER2 and DNA Repair - Stars at Night Ballroom 1&2 - 3rd Level
Chair: Ian Krop, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
Discussants
DNA repair
Jennifer Litton, MD
UT MD Anderson Cancer Center
Houston, TX
HER2
Antonio Wolff, MD, FACP, FASCO
Johns Hopkins School of Medicine
Baltimore, MD |
|
| |
|
|
| 7:00 am - 9:00 am |
SPOTLIGHT SESSION 5:
Immunooncology
Biomarkers and the Immune Landscape of Breast Cancer - Stars at Night Ballroom 3&4 - 3rd Level
Chair: Heather McArthur, MD, MPH
Cedars-Sinai
Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA
Discussants:
IO/PDL1
Ashley Cimino-Mathews, MD
Johns Hopkins University School of Medicine
Baltimore, MD
TILs/Clinical correlatatives
Heather McArthur, MD, MPH
Cedars-Sinai
Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA |
|
| |
|
|
|
7:00 am - 9:00 am
|
POSTER SESSION 2 & continental breakfast
- Hall 1
|
|
|
|
Detection/Diagnosis
|
|
|
|
Imaging and Screening - Radiology - Tumor Monitoring
Imaging and Screening - Screening
Other
|
P2-01
P2-02
P2-03
|
| |
Tumor Cell and Molecular Biology |
|
|
|
Cellular Mechanisms
DNA Damage and Repair
Stem/Progenitor Cells
Growth Factors
|
P2-04
P2-05
P2-06
P2-07
|
| |
Epidemiology, Risk, and Prevention |
|
| |
Population Studies
Genetic and Molecular
Ethnic/Racial Aspects
|
P2-08
P2-09
P2-10
|
| |
|
|
| |
Prognostic and Predictive Factors |
|
| |
Biomarkers Predicting Treatment Sensitivity and Resistance - Predictive Biomarkers for Endocrine Therapies
|
P2-11 |
| |
|
|
| |
Psychosocial, Quality of Life, and Educational Aspects |
|
| |
Supportive Care
Survivorship Research |
P2-12
P2-13 |
|
|
|
| |
Treatment |
|
| |
Adjuvant Therapy - Adjuvant Chemotherapy
Advanced Disease Treatment - Advanced Chemotherapy
Therapeutic Strategies - Neoadjuvant Chemotherapy
Advanced Disease Treatment - Advanced Therapy - Other
Adjuvant Therapy - Other
Types and Sites of Breast Cancer - Bone Metastases
Types and Sites of Breast Cancer - Brain Metastases
Research Resources - Tissue and Data Banks |
P2-14
P2-15
P2-16
P2-17
P2-18
P2-19
P2-20
P2-21 |
| |
|
|
|
9:00 am - 9:30 am
|
PLENARY LECTURE 2
– Hall 3 |
|
|
|
The Role of Radiotherapy Combined With Immunotherapy in Oligometastatic Cancer
Ralph R. Weichselbaum, MD
University of Chicago
Chicago, IL
|
|
|
|
|
|
|
9:30 am - 11:30 am
|
GENERAL SESSION 3
– Hall 3
Moderator: TBD
|
|
| 9:30 am |
GS3-01. Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study |
|
| |
Blohmer J-U, Link T, Kummel S, Untch M, Just M, Fasching PA, Schneeweiss A, Wimberger P, Stotzer O, Huober J, Thill M, Jackisch C, Rhiem K, Hanusch C, Denkert C, Engels K, Nekljudova V, Loibl S. Gynakologie mit Brustzentrum Charite Universitatsmedizin, Berlin, Germany; Department of Gynecology and Obstetrics, Medical Faculty andUniversity Hospital Carl Gustav Carus, Technische Universitat Dresden, Dresden, Germany; Kliniken Essen Mitte, Essen,Germany; HELIOS Kliniken Berlin-Buch, Berlin, Germany; Onkologische Schwerpunktpraxis, Bielefeld,Germany; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer CenterErlangen-EMN, Erlangen, Germany; Nationales Centrum fur Tumorerkrankungen, Heidelberg,Germany; Universitatsklinikum, Dresden, Germany; Hamatoonkologische Schwerpunktpraxis, Munchen,Germany; Universitatsklinikum, Ulm, Germany; Agaplesion Markus Krankenhaus, Frankfurt, Germany; Sana Klinikum,Offenbach, Germany; Zentrum Familiarer Brust- und Eierstockkrebs, Universitatsklinikum, Koln,Germany; Rotkreuzklinikum, Munchen, Germany; Institut fur Pathologie Philipps-Universitat, Marburg, Germany; Zentrumfur Pathologie, Zytologie und Molekularpathologie, Neuss, Germany; German Breast Group, Neu-Isenburg, Germany. |
|
| |
|
|
| 9:45 am |
GS3-02. Durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: Results from phase II randomized trial SAFIR02-IMMUNO |
|
| |
Dalenc F, Garberis I, Filleron T, Lusque A, Bachelot T, Arnedos M, Campone M, Sablin M-P, Bonnefoi H, Jimenez M, Alexandra J, Andre F. Institut Claudius Regaud, Toulouse, France; Gustave Roussy, Villejuif, France; Centre Leon Berard, Lyon, France; Institut deCancerologie de l'Ouest, Saint-Herblain / Angers, France; Institut Curie, Paris / Saint-Cloud, France; Institut Bergonie,Bordeaux, France; Unicancer, Kremlin Bicetre, France. |
|
| |
|
|
| 10:00 am
|
GS3-03. Keynote-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early triple-negative breast cancer: pathologic complete response in key subgroups and by treatment exposure, residual cancer burden, and breast-conserving surgery
|
|
| |
Schmid P, Park YH, Ferreira M, Mouret-Reynier M-A, Im S-A, Ahn J-H, Gion M, Hui R, Baron-Hay S, Boileau J-F, Liu M-C, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Andersen J, Untch M, Tokar M, Dalenc F, Danso M, Patt D, Kümmel S, Denkert C, Pusztai L, Bergh J, McArthur H, Jia L, Aktan G, Karantza V, Dent R, Cortes J, O'Shaughnessy J. Barts Cancer Institute, Centre for Experimental Cancer Medicine, London, United Kingdom; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Instituto Português de Oncologia do Porto Francisco Gentil (IPO-Porto), Porto, Portugal; Centre Jean-Perrin, Clermont-Ferrand, France; Seoul National University, Seoul, Republic of Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Ramon y Cajal University Hospital, Madrid, Spain; Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia; McGill University, Jewish General Hospital Segal Cancer Centre, Montréal, Québec, Canada; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, Republic of China; Breast Center, University of Munich (LMU), Munich, Germany; Hokkaido Cancer Center, Sapporo, Japan; Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer theme, Karolinska University Hospital, Solna, Sweden; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal; Compass Oncology, US Oncology, Portland, OR; Breast Cancer Center, Helios Klinikum Berlin Buch, Berlin, Germany Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Institut Claudius-Regaud, IUCT-oncopôle, Toulouse, France; Virgina Oncology Associates, Norfolk, VA; Texas Oncology, Austin, TX; Kliniken Essen-Mitte, Essen, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Yale School of Medicine, Yale Cancer Center, New Haven, CT; Cedars-Sinai Medical Center, Los Angeles, CA; Merck & Co., Inc., Kenilworth, NJ; University of Toronto, Toronto, Ontario, Canada; IOB Institute of Oncology, Quiron Group; Vall d'Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain; Texas Oncology, Dallas, TX.
|
|
| |
|
|
| 10:15 am
|
GS3-04. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
|
|
|
|
Gianni L, Huang C, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, Ciruelos E, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Maffeis I, Valagussa P, Viale G. Fondazione Michelangelo, Milano, Italy; National Taiwan University Hospital and Taiwan Breast Cancer Consortium, Taipei, Taiwan; BrustGesundheitZentrum Tirol, Medical University Innsbruck, Innsbruck, Austria; Hospital Clinico Universitario, Valencia, Spain; Policlinico S. Orsola Malpighi SSD Oncologia Medica Addarii, Bologna, Italy; Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany; Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain; San Raffaele Hospital, Milano, Italy; Ospedale Santa Maria della Misericordia, Udine, Italy; Hospital Universitario 12 de Octubre, Madrid, Spain; Paracelsus Medical University Salzburg; Salzburg Cancer and Cancer cluster, Salzburg, Austria; NN Petrov Research Inst of Oncology, St Petersburg, Russian Federation; Istituto Europeo di Oncologia, Milano, Italy; Cancer Trials Ireland & Mater Misericordiae University Hospital, Dublin, Ireland; IRCCS Istituto Nazionale Tumori, Milano, Italy; Università degli Studi di Genova, Ospedale Policlinico San Martino, Genova, Italy.
|
|
| |
|
|
|
10:30 am
|
GS3-05. Discussant
Kevin Kalinsky, MD, MS
Columbia University Irving Medical Center
New York, NY
|
|
| |
|
|
| 10:45 am |
GS3-06. Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010) |
|
| |
Turner N, Kingston B, Kilburn L, Kernaghan S, Wardley AM, Macpherson I, Baird RD, Roylance R, Stephens P, Oikonomidou O, Braybrooke JP, Tuthill M, Abraham J, Winter MC, Bye H, Hubank M, Snowdon C, Rea D, Cameron D, Shaaban A, Randle K, Wilkinson K, Moretti L, Bliss JM, Ring A, on behalf of the plasmaMATCH Trial Management Group. The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom; Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom; The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust and Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Manchester, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Cancer Research UK Cambridge Centre, Cambridge, United Kingdom; University College London Hospitals NHS Foundation Trust and NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom; Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom; Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom; University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; Velindre University NHS Trust, Cardiff, United Kingdom; Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; The Royal Marsden NHS Foundation Trust, Sutton and The Institute of Cancer Research, London, United Kingdom; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Independent Cancer Patients' Voice, London, United Kingdom. |
|
| |
|
|
|
11:00 am
|
GS3-07. The genomic landscape of breast cancer based on ctDNA analysis: data from the plasmaMATCH trial
|
|
|
|
Kingston B, Bye H, Hubank M, Walsh G, Swift C, Beaney M, Kilburn L, Kernaghan S, Wardley AM, Macpherson I, Baird RD, Roylance R, Wilkinson K, Garcia-Murillas I, Bliss JM, Turner N, Ring A, on behalf of the plasmaMATCH Trial Management Group. The Institute of Cancer Research, London, United Kingdom; The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; The Royal Marsden NHS Foundation Trust, Sutton and The Institute of Cancer Research, London, United Kingdom; Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom; The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust and Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine & Health, University of Manchester, Manchester, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Cancer Research UK Cambridge Centre, Cambridge, United Kingdom; University College London Hospitals NHS Foundation Trust, and NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom. |
|
|
|
|
|
|
11:15 am
|
GS3-08. Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network
|
|
| |
King TA, Liu MC, McClure MB, Hinoue T, Kelly BJ, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Rezk S, Garrett AL, Balko JM, Parker JS, Park BH, Krop I, Anders C, Hoadley KA, Gastier-Foster J, Rimawi MF, Nanda R, Lin NU, Isaacs C, Marcom P, Storniolo A, Couch FJ, Mardis ER, Lee AV, Chandran U, Laird PW, Hilsenbeck SG, Norton L, Richardson AL, Symmans W, Carey LA, Wolff AC, Davidson NE, Perou CM, the AURORA US Network. Dana Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of North Carolina, Chapel Hill, NC; Van Andel Research Institute, Grand Rapids, MI; Nationwide Children’s Hospital, Columbus, OH; Baylor College of Medicine, Houston, TX; Translational Breast Cancer Research Consortium, Baltimore, MD; Vanderbilt University Medical Center, Nashville, TN; Duke University, Durham, NC; University of Chicago, Chicago, IL; Georgetown University, Washington DC, DC; Indiana University School of Medicine, Indianapolis, IN; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Johns Hopkins University, Baltimore, MD; MD Anderson Cancer Center, Houston, TX; Fred Hutchinson Cancer Research Center, Seattle, WA. |
|
| |
|
|
| 10:45 am - 5:00 pm |
EXHIBITS - Hall 2 |
|
| |
|
|
|
11:30 am - 12:00 pm |
AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH - Hall 3
|
|
| |
Essential Genes and Cistromes in Breast Cancer
Myles Brown, MD
Dana-Farber Cancer Institute
Boston, MA |
|
| |
|
|
|
12:00 pm - 1:00 pm |
BREAK |
|
|
|
|
|
| 12:00 pm - 1:00 pm |
CAREER DEVELOPMENT FORUM - Room 304
|
|
| |
Panel Q&A: Getting the Most from Your Training
A distinguished panel of researchers will answer questions from the audience and provide advice for a candid view into the skills, work, and resources needed for a productive and fulfilling traineeship. Panelists represent the spectrum of basic to clinical researchers, ensuring that students, postdoctoral fellows and medical residents alike receive valuable insight on their fellowships. Please join us for an inside look into how to get the most from your training!
Panelists:
E. Shelley Hwang, MD, MPH
Duke Cancer Institute
Durham, NC
Geoffrey Wahl, PhD
The Salk Institute for Biological Studies
La Jolla, CA
Alana L. Welm, PhD
University of Utah Huntsman Cancer Institute
Salt Lake City, UT
Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA |
|
| |
|
|
|
1:00 pm - 2:00 pm
|
CASE DISCUSSION 1 – Stars at Night Ballroom 1&2 - 3rd Level
|
|
|
|
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
Panelists:
Tari A. King, MD
Dana-Farber Cancer Center
Boston, MA
Pierfranco Conte, MD
University of Padova
Padova, ITALY
Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN
Benjamin Smith, MD
UT MD Anderson Cancer Center
Houston, TX
Medha Deoras-Sutliff
The US EHE Foundation
Newark, OH
|
|
| |
|
|
|
1:00 pm - 2:00 pm
|
TRANSLATIONAL SCIENCE FORUM 1 - Stars at Night Ballroom 3&4 - 3rd Level |
|
|
|
Proteogenomics of Breast Cancer, from Discovery to Precision Medicine
Moderator: Matthew J. Ellis, MD, BChir, BSc, PhD FRCP
Baylor College of Medicine
Lester & Sue Smith Breast Center
Houston, TX
Advanced enabling technologies for cancer proteomics
Tao Liu, PhD
Pacific Northwest National Laboratory
Richland, WA
Proteogenomic landscape of prospectively collected breast cancer
Michael Gillette, MD, PhD
Broad Institute
Cambridge, MA
Proteogenomics and clinical translation
Matthew J. Ellis, MB, BChir, BSc, PhD, FRCP
Baylor College of Medicine
Houston, TX
|
|
| |
|
|
|
2:15 pm - 3:15 pm
|
MINI-SYMPOSIUM 1 - Hall 3 |
|
|
|
Future of Immuno-oncology in Breast Cancer
Moderators:
Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX
and
Helen Heslop, MBChB, MD, DSc
Baylor College of Medicine
Houston, TX
Immunotherapy in breast cancer: enhancing response to checkpoint blockade
Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Cancer Institute
Brigham and Women's Cancer Center
Boston, MA
T cell-based immunotherapy for a "public" neoantigen derived from a PIK3CA hotspot mutation
Christopher A. Klebanoff, MD
Memorial Sloan Kettering Cancer Center
New York, NY
|
|
|
|
|
|
|
3:15 pm - 5:00 pm
|
GENERAL SESSION 4
– Hall 3
Moderator: Susan Domchek, MD
University of Pennsylvania
Philadelphia, PA
|
|
|
|
|
|
|
3:15 pm
|
GS4-01. Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI)
|
|
|
|
Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL III, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N. NRG Oncology, and Orlando Health UF Health Cancer Center, Orlando, FL; NRG Oncology, and University of Pittsburgh, Pittsburgh, PA; NRG Oncology, and Virginia Commonwealth University School of Medicine Massey Cancer Center, Richmond, VA; NRG Oncology, and Kaiser Permanente Oncology Clinical Trials Northern, Novato, CA; NRG Oncology, and Waverly Hematology Oncology, Cary, NC; NRG Oncology, and British Columbia Cancer Agency, Vancouver, BC, Canada; NRG Oncology, and University of Pittsburgh, Magee-Womens Hospital, Pittsburgh, PA; Cancer Trials Ireland (Formerly known as Irish Clinical Oncology Research Group – ICORG), Dublin, Ireland; NRG Oncology, and Florida Cancer Specialists, Fort Myers, FL; NRG Oncology, and CCOP Wichita via Christi Reg. Med. Ctr., Wichita, KS; NRG Oncology, and Atlanta Cancer Care, Atlanta, GA; NRG Oncology, and Decatur Memorial Hospital/Cancer Care Specialists of Illinois/Heartland NCORP, Decatur, IL; NRG Oncology, and Medstar Franklin Square Medical Center, Baltimore, MD; NRG Oncology, and Yonsei University College of Medicine, Seoul, Korea, Republic of; NRG Oncology, and Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; NSABP/NRG Oncology, Pittsburgh, PA. |
|
| 3:30 pm
|
GS4-02. Investigating genomic and phenotypic evolution of triple negative breast cancer chemoresistance and metastasis in patient-derived xenografts
|
|
|
|
Echeverria GV, Xu M, Shao J, Zhang X, Jeter-Jones S, Zhou X, Moulder SL, MarszalekJR, Heffernan TP, Symmans FW, Chang JT, Piwnica-Worms H. The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX. |
|
| 3:45 pm
|
GS4-03. Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study
|
|
|
|
Sestak I, Crager M, Cuzick J, Dowsett M, Shak S, Tang G, Gray R, Sparano J. Centre for Cancer Prevention, London, United Kingdom; Genomic Health, Redwood City, CA; Ralph Lauren Centre for Breast Cancer Research, London, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Dana Farber Cancer Institute, Boston, MA; Albert Einstein College of Medicine, New York, NY. |
|
|
4:00 pm
|
GS4-04. Ten year results of the international breast cancer intervention study II
|
|
|
|
Cuzick J, Sestak I, Forbes J, Dowsett M, Cawthorn S, Mansell R, Loibl S, Bonanni B, Howell A, IBIS-II investigators. Centre for Cancer Prevention, London, United Kingdom; School of Medicine and Public Health, Newcastle, Australia; Ralph Lauren Centre for Breast Cancer Research, London, United Kingdom; North Bristol NHS Trust, Bristol, United Kingdom; Cardiff University, Cardiff, United Kingdom; German Breast Group, Frankfurt, Germany; Istituto Europeo di Oncologia, Milan, Italy; University of Manchester, Manchester, United Kingdom.
|
|
| 4:15 pm |
GS4-05. Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X
|
|
| |
To be presented by Fatima Cardoso
Piccart MJ, Poncet C, Cardoso F, van't Veer L, Delaloge S, Pierga J, Brain E, Vrijaldenhoven S, Neijenhuis P, Aalders K, Rutgers E. Institute Jules Bordet, Université Libre de Belgique, Brussels, Belgium; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal; University California San Francisco, San Francisco, CA; Gustave Roussy, Unicancer Breast Group UCBG, Villejuif, France; Institut Curie Paris & St Cloud, Université Paris Descartes, Paris, France; Institut Curie - Hôpital Rene Huguenin, Saint Cloud, France; Noordwest Ziekenhuisgroep - Site Alkmaar, Alkmaar, Netherlands; Rijnland Ziekenhuis-Alrijne Zorgroep, Leiderdop, Netherlands; Gelre Hospital, Apeldoorn, Netherlands; Netherlands Cancer Institute, Amsterdam, Netherlands. |
|
|
4:30 pm
|
GS4-06. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial
|
|
| |
Meattini I, Saieva C, Lucidi S, lo Russo M, Scotti V, Desideri I, Marrazzo L, Simontacchi G, Mangoni M, Becherini C, Visani L, Paoletti L, Moretti E, Triggiani L, Bernini M, Orzalesi L, Sanchez L, Nori J, Pallotta S, Bianchi S, Livi L. University of Florence, Florence, Italy; Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Florence, Italy; Ospedale Santa Maria Annunziata - Azienda Usl Toscana centro, Florence, Italy; Ospedale S. Stefano - Azienda Usl Toscana centro, Prato, Italy; University of Brescia, Brescia, Italy. |
|
| 4:45 pm |
GS4-07. Costs and effects in the first randomized trial comparing MRI breast cancer screening with mammography in women with a familial risk: FaMRIsc
|
|
| |
Tilanus-Linthorst MMA, Geuzinge HA, Obdeijn IM, Rutgers EJT, Mann RM, Saadatmand S, de Roy van Zuidewijn DBW, Tollenaar RAEM, Lobbes MBI, Ausems MGEM, van 't Riet M, Hooning MJ, Wesseling J, Mares-Engelberts I, Luiten EJT, Oosterwijk JC, Heijnsdijk EAM, de Koning HJ. Erasmus University MC, Rotterdam, Netherlands; The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Radboud University Hospital, Nijmegen, Netherlands; Medical Center Leeuwarden, Leeuwarden, Netherlands; Leiden University MC, Leiden, Netherlands; Academic Hospital Maastricht, Maastricht, Netherlands; University MC Utrecht, Utrecht, Netherlands; Reinier de Graaf Gasthuis, Delft, Netherlands; Vlietland Ziekenhuis, Schiedam, Netherlands; Amphia Ziekenhuis, Breda, Netherlands; University MC Groningen, Groningen, Netherlands. |
|
| |
|
|
|
5:00 pm - 7:00 pm
|
SPOTLIGHT SESSION 6: Local Regional Therapy/DCIS – Hemisfair Ballroom - 3rd Level
Chair: Karen Hoffman, MD
UT MD Anderson Cancer Center
Houston, TX
Discussants:
Surgery
Andrea Barrio, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY
Radiation
Karen Hoffman, MD
UT MD Anderson Cancer Center
Houston, TX
DCIS
Fariba Behbod, Pharm.D., PhD
University of Kansas
Kansas City, KS
|
|
| |
|
|
| 5:00 pm - 7:00 pm |
SPOTLIGHT SESSION 7: The Science of ER
Resistance and Emerging Clinical Strategies - Stars at Night Ballroom 1&2 - 3rd Level
Chair: Stacy Moulder, MD
UT MD Anderson Cancer Center
Houston, TX
Discussants:
Science of ER resistance
David Cescon, MD
Princess Margaret Cancer Centre
Toronto, CANADA
Novel drugs for ER metastasis
Rachel M. Layman, MD
UT MD Anderson Cancer Center
Houston, TX
|
|
| |
|
|
| 5:00 pm - 7:00 pm |
SPOTLIGHT SESSION 8: The Metastatic Landscape - Drug Resistance and Metastasis Biology - Stars at Night Ballroom 3&4 - 3rd Level |
|
| |
Chair: Alana Welm, PhD
University of Utah Huntsman Cancer Institute
Salt Lake City, UT
Discussants:
Genomic studies in metastasis
Alana Welm, PhD
University of Utah Huntsman Cancer Institute
Salt Lake City, UT
Metastasis biology
Shridar Ganesan, MD, PhD
Rutgers Cancer Institute
New Brunswick, NJ
|
|
| |
|
|
|
5:00 pm - 7:00 pm
|
POSTER SESSION 3 & reception – Hall 1 |
|
|
|
|
|
| |
Tumor Cell and Molecular Biology |
|
|
Tumor Progression, Invasion, and Metastasis
Metabolism and Breast Cancer
Signaling Pathways
Telomeres/Telomerase
Other
Novel/Emerging Therapeutic Targets
|
P3-01
P3-02
P3-03
P3-04
P3-05
P3-06
|
|
|
|
|
|
|
Prognostic and Predictive Factors
Prognostic Factors - Prognostic Factor Index Scores
Other
|
P3-07
P3-08
|
|
|
|
|
|
|
Treatment
Therapeutic Strategies - Immunotherapy (Clinical)
Therapeutic Strategies - Novel Targets and Targeted Agents
Therapeutic Strategies - New Drug and Treatment Strategies
Therapeutic Strategies - Antiangiogenic Therapy (Adjuvant and Metastatic)
Therapeutic Strategies - Signal Transduction Inhibitors
Adjuvant Therapy - Targeted
|
P3-09
P3-10
P3-11
P3-12
P3-13
P3-14
|
|
|
|
| |
Ongoing Trials
Targeted - HER2
Targeted - CDK4/6
Targeted - PARP
Targeted - PD-1/PD-L1
Targeted - VEGFR
Targeted - PI3K
Targeted - FGFR
Targeted - AKT
Targeted - Microtubules
|
OT2-01
OT2-02
OT2-03
OT2-04
OT2-05
OT2-06
OT2-07
OT2-08
OT2-09
|
| |
|
|
| 7:30 pm |
OPEN SATELLITE EVENT presented by Harborside Medical Education - Marriott Rivercenter
Breast Cancer Brain Metastases: Key Strategies for Optimal Management
For further information and to register for this event, visit https://www.eventbrite.com/e/breast-cancer-brain-metastases-key-strategies-for-optimal-management-registration-71692294583
|
|
| |
|
|
| 7:30 pm |
OPEN SATELLITE EVENT presented by Research to Practice - Marriott Rivercenter, Grand Ballroom G-M
Data + Perspectives: Clinical Investigators Explore the Current and Future Management of Triple-Negative Breast Cancer
For further information and to register for this event, visit
http://www.researchtopractice.com/Meetings/SA2019
|
|
|